Effects of Opuntia megacantha on blood glucose and kidney function in streptozotocin diabetic rats

P Bwititi1, C T Musabayane, C F Nhachi

  • 1Department of Medical Laboratory Sciences, Faculty of Medicine, University of Zimbabwe, Harare.

Insights

Opuntia megacantha leaf extracts lowered blood glucose in rats but may harm kidneys. The extracts increased urinary sodium and elevated plasma urea and creatinine, indicating potential kidney toxicity.

Area of Science:

  • Pharmacology
  • Nephrology
  • Diabetology

Background:

  • Diabetes mellitus is a metabolic disorder characterized by hyperglycemia.
  • Kidney dysfunction is a common complication of diabetes.
  • Herbal remedies are explored for managing diabetes and its complications.

Purpose of the Study:

  • To investigate the effects of Opuntia megacantha leaf extracts on blood glucose and kidney function.
  • To assess the impact of O. megacantha on normal and streptozotocin (STZ)-induced diabetic rats.

Main Methods:

  • Rats (normal and STZ-diabetic) were orally administered O. megacantha leaf extracts (20 mg/100 g body weight) or saline daily for 5 weeks.
  • Urine volume, urinary Na+, K+, and creatinine output were monitored.
  • Plasma Na+, K+, urea, creatinine, and glomerular filtration rate (GFR) were determined.

Main Results:

  • O. megacantha leaf extracts reduced plasma glucose concentrations in both normal and STZ-diabetic rats.
  • Extracts increased urinary Na+ output and decreased plasma Na+ concentration.
  • Significant elevations in plasma creatinine and urea were observed, suggesting kidney impairment.
  • GFR increased in STZ-diabetic rats but remained unchanged in normal rats.

Conclusions:

  • Opuntia megacantha leaf extracts demonstrate hypoglycemic effects.
  • The extracts may possess nephrotoxic properties, evidenced by increased plasma urea and creatinine and decreased plasma sodium.
  • Further research is warranted to elucidate the mechanisms and safety profile of O. megacantha for kidney function.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...